Literature DB >> 6262087

Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6262087     DOI： 10.1016/0014-2964(80)90064-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  78 in total

1.  Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.

Authors:  Jamal Zidan; Zohar Keidar; Walid Basher; Ora Israel
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma.

Authors:  B Vandewalle; M Collyn d'Hooghe; J B Savary; M O Vilain; J P Peyrat; M Deminatti; A Delobelle-Deroide; J Lefebvre
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Nuclear pleomorphism, a strong prognostic factor in axillary node-negative small invasive breast cancer.

Authors:  M Stierer; H Rosen; R Weber
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

4.  Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies.

Authors:  N Falette; M F Lefebvre; F Meggouh; M Eynard; E Garin; S Saez
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

5.  Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology.

Authors:  S Romain; F Spyratos; J Goussard; J L Formento; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

7.  Changes in oestrogen, progesterone and epidermal growth factor receptor concentrations and affinities during the oestrous cycle in the normal mammary gland and uterus of dogs.

Authors:  I Donnay; P Wouters-Ballman; N Devleeschouwer; G Leclercq; J Verstegen
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

8.  Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.

Authors:  A Vering; A Vockel; M Stegmüller; H G Bender
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.

Authors:  A Berthier; S Seguin; A J Sasco; J Y Bobin; G De Laroche; J Datchary; S Saez; C Rodriguez-Lafrasse; F Tolle; A Fraichard; M Boyer-Guittaut; M Jouvenot; R Delage-Mourroux; F Descotes
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

10.  Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Authors:  Anne-Sofie Schrohl; Maxime P Look; Marion E Meijer-van Gelder; John A Foekens; Nils Brünner
Journal:  BMC Cancer       Date:  2009-09-10       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.